国产精品ⅴ无码大片在线看,激情影院内射美女,动物与人性生活一区二区三区性生活激情视频,久久久久免费毛a片免费一瓶梅

尊龍凱時(shí)·(中國(guó)區(qū))人生就是搏!

EN
×
EN

  • 業(yè)務(wù)咨詢

    中國(guó)：

    Email: marketing@www.msjidi.com

    業(yè)務(wù)咨詢專線：400-780-8018

    （僅限服務(wù)咨詢，其他事宜請(qǐng)撥打川沙總部電話）

    川沙總部電話: +86 (21) 5859-1500

    海外：

    +1(781)535-1428(U.S.)

    0044 7790 816 954 (Europe)

    Email:marketing@medicilon.com
在線留言×

搜索結(jié)果包含 Compound 的內(nèi)容

Jul 10,2025
TBN是一種治療缺血性卒中的新型臨床候選藥物，本研究中TBN通過尊龍凱時(shí)合成
TBN (purity 99.3%) used in this study was synthesized by Medicilon.
查看更多
Jul 10,2025
跨膜結(jié)構(gòu)域寡聚體的結(jié)構(gòu)測(cè)定新方法，其中TriNTA通過尊龍凱時(shí)合成
TriNTA was synthesized by Medicilon.
查看更多
Jul 03,2025
特異性RET抑制劑CPT可改善阿爾茨海默病，本研究中CPT由尊龍凱時(shí)化學(xué)部門合成
The compound was synthesized for Cerepeut Inc. by the Chemistry Branch of Medicilon.
查看更多
Jul 02,2025
口服有效的ADAMTS-4/5抑制劑異吲哚啉酰胺衍生物，可治療骨關(guān)節(jié)炎，本研究中部分化合物通過尊龍凱時(shí)合成
Part of the compound synthesis was performed at Medicilon.
查看更多
Jul 06,2023
設(shè)計(jì)合成一系列用于治療胃癌的多靶點(diǎn)受體酪氨酸激酶抑制劑，并進(jìn)行生物學(xué)評(píng)價(jià)。其中藥代動(dòng)力學(xué)分析通過尊龍凱時(shí)進(jìn)行
Gastric cancer is the second most lethal cancer across the world. Compounds 8f, inhibits FGFR1 signaling pathways as well as induces cell apoptosis, is a potential agent for the treatment of gastric c
查看更多
Jul 06,2023
FBPase是與腫瘤和2型糖尿病相關(guān)的一個(gè)有前景的靶點(diǎn)。化合物W8對(duì)FBPase表現(xiàn)出高選擇性。W8的藥代動(dòng)力學(xué)研究通過尊龍凱時(shí)進(jìn)行
Fructose-1,6-bisphosphatase (FBPase) is a promising target associated with cancer and type 2 diabetes. Compounds W8 and W8k exhibit high selectivity against FBPase and W8 effectively reduces blood glu
查看更多
Jul 06,2023
藥物發(fā)現(xiàn)中的挑戰(zhàn)之一是識(shí)別高質(zhì)量的先導(dǎo)化合物。此研究中PK結(jié)果表明L12可作為針對(duì)PDE5的先導(dǎo)化合物，進(jìn)一步研究和開發(fā)。L12的PK分析通過尊龍凱時(shí)進(jìn)行
Scaffold hopping refers to computer-aided screening for active compounds with different structures against the same receptor to enrich privileged scaffolds, which is a topic of high interest in organi
查看更多
Jul 06,2023
XY153是一種有潛力的先導(dǎo)化合物，可用于開發(fā)針對(duì)急性髓系白血病。XY153在體外具有良好的代謝穩(wěn)定性。所有肝微粒體測(cè)定均通過尊龍凱時(shí)進(jìn)行
Pan-bromodomain and extra terminal (Pan-BET) inhibitors show profound efficacy but exhibit pharmacology-driven toxicities in clinical trials. The representative Compound 8l (XY153), a novel BD2-select
查看更多
Jul 06,2023
基于構(gòu)效關(guān)系分析，合成了一種結(jié)構(gòu)簡(jiǎn)化但具有優(yōu)異防污活性的化合物。優(yōu)化后的化合物通過尊龍凱時(shí)合成
Biofouling poses one of the most serious problems to marine industry and aquaculture development. Five structurally similar compounds were isolated from the crude extract of a marine Streptomyces stra
查看更多
Jul 06,2023
PDE1是與中樞和外周疾病密切相關(guān)的藥物靶點(diǎn)，研究人員合成一種PDE1 抑制劑在大鼠肝微粒體中具有良好的代謝穩(wěn)定性。其中穩(wěn)定性測(cè)試通過尊龍凱時(shí)進(jìn)行
Phosphodiesterase-1 (PDE1) is a promising drug target closely related to central and peripheral diseases. Compound 2j with the IC50 of 21 nM against PDE1B, shows good metabolic stability in the rat li
查看更多
Jun 28,2023
開發(fā)并驗(yàn)證新的LC-MS/MS方法，用于定量人血漿中達(dá)拉非尼及其主要代謝物羥基達(dá)拉非尼 (OHD)。本研究中OHD(純度>99%)通過尊龍凱時(shí)合成
OHD (purity >99 %) was synthesized by Medicilon. Medicilon synthetic chemistry team is capable of the independent design of synthesis pathways and complex compound treatments, key to helping accelerate drug discovery.
查看更多
99%)通過尊龍凱時(shí)合成">
Jun 28,2023
SKLB-197是一種有效且高度選擇性的ATR抑制劑，PK研究通過尊龍凱時(shí)進(jìn)行
SKLB-197, exhibits good pharmacokinetic properties, could be a promising lead compound for drug discovery targeting ATR. The pharmacokinetic (PK) studies were performed by Medicilon.
查看更多
Jun 28,2023
研究用于肺癌和黑色素瘤細(xì)胞肺轉(zhuǎn)移的選擇性PAK4抑制劑的合成，此選擇性PAK4抑制劑的PK研究通過尊龍凱時(shí)進(jìn)行
The p21 activated kinase 4 (PAK4) is serine/threonine protein kinase that is critical for cancer progression. 6-Ethynyl-1H-indole derivative 55 is a potent and selective PAK4 inhibitor (Ki=10.2 nM). Compound 55 is effective in the treatment of metastatic
查看更多
May 29,2023
美研 | Beautiful Chemistry Issue 4 : Direct Cyclopropanation by Organoelectrocatalysis
In summary, the efficient and scalable intramolecular cyclopropanation of active methylene compounds via electrocatalysis with an organic catalyst can solve challenges from the transition metal catalyzed alkene cyclopropanation of functionalized compound
查看更多

川沙總部

地址: 上海市浦東新區(qū)川大路585號(hào)

郵編: 201299

電話: +86 (21) 5859-1500（總機(jī)）

傳真: +86 (21) 5859-6369

業(yè)務(wù)咨詢

中國(guó)：

Email: marketing@medicilon.com

業(yè)務(wù)咨詢專線：400-780-8018

（僅限服務(wù)咨詢，其他事宜請(qǐng)撥打川沙
總部電話）

 

海外：

Email:?marketing@medicilon.com

Tel: +1 (617) 888-9294(U.S.)

Tel: 0044 7790 816 954 (Europe)

Tel: +82 70-8269-5849 (Korea)

Tel: +81 80-4421-6898 (Japan)

? 2022 上海尊龍凱時(shí)生物醫(yī)藥股份有限公司 保留所有權(quán)利 滬ICP備10216606號(hào)-3
滬公網(wǎng)安備 31011502012909號(hào)|網(wǎng)站地圖|技術(shù)支持：集錦科技
安全性評(píng)價(jià) 溶瘤病毒 PDX模型 IND申報(bào) AAALAC
×
搜索驗(yàn)證